⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ARVN News
Arvinas, Inc
Form 8-K
sec.gov
ARVN
RIGL
PFE
Form 8-K
sec.gov
ARVN
Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com
ARVN
RIGL
PFE
Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
globenewswire.com
ARVN
PFE
RIGL
PARP Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
globenewswire.com
AZN
MRK
JNJ
PFE
ABBV
GSK
ALLR
SNY
CURI
ORIC
EXEL
ABSI
LLY
TLX
FPH
BMY
SNX
XNCR
ZENA
ARVN
MGNX
DASH
VERU
GILD
EVGN
GEN
AMGN
MIR
RXRX
BG
MTX
BIO
Catalyst Monitor: Q2 2026 Outlook Report - Trial Initiations, Completions, Top-line Results, Regulatory Filings, PDUFA Dates, and Expected Approvals
globenewswire.com
RPTX
ARVN
RGNX
Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026
globenewswire.com
ARVN
Form 8-K
sec.gov
ARVN
PFE
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
globenewswire.com
ARVN
PFE
Arevon Earns Gold Certification for Diversity, Equity, Inclusion, and Justice Initiatives from the Solar Energy Industries Association
prnewswire.com
ARVN